Literature DB >> 21339701

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.

Christopher J Gill1, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro, Peter Dull.   

Abstract

The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21339701      PMCID： PMC3060384          DOI： 10.4161/hv.6.11.12849

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  16 in total

1.  Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.

Authors:  Cressida Auckland; Stephen Gray; Ray Borrow; Nick Andrews; David Goldblatt; Mary Ramsay; Elizabeth Miller
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

2.  Meningococcal disease and vaccination in North America.

Authors:  A J Pollard; D Scheifele
Journal:  J Paediatr Child Health       Date:  2001-10       Impact factor: 1.954

Review 3.  Meningococcal surrogates of protection--serum bactericidal antibody activity.

Authors:  Ray Borrow; Paul Balmer; Elizabeth Miller
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

4.  Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-09-25       Impact factor: 17.586

5.  Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

Authors:  Mehmet Ceyhan; Inci Yildirim; Paul Balmer; Christine Riley; Gouri Laher; Nick Andrews; Ray Borrow; Nese Kurt; Mehmet Turgut; Aysel Aydogan; Cigdem Ecevit; Gulnar Uysal; Viola Schultze
Journal:  Vaccine       Date:  2007-08-01       Impact factor: 3.641

Review 6.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

7.  Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Authors:  Lisa A Jackson; Roger Baxter; Keith Reisinger; Annette Karsten; Jina Shah; Lisa Bedell; Peter M Dull
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

8.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

Review 9.  Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.

Authors:  Carl E Frasch; Ray Borrow; John Donnelly
Journal:  Vaccine       Date:  2009-05-21       Impact factor: 3.641

Review 10.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321
View more
  30 in total

Review 1.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

2.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

3.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

4.  UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  This Statement Was Prepared By Dr B Warshawsky
Journal:  Can Commun Dis Rep       Date:  2013-01-02

5.  Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.

Authors:  Sarah Mbaeyi; Tracy Pondo; Amy Blain; David Yankey; Caelin Potts; Amanda Cohn; Susan Hariri; Nong Shang; Jessica R MacNeil
Journal:  JAMA Pediatr       Date:  2020-09-01       Impact factor: 16.193

Review 6.  Meningococcal vaccines: current issues and future strategies.

Authors:  Amanda C Cohn; Lee H Harrison
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 7.  Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Authors:  Jamie D Croxtall; Sohita Dhillon
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 8.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

9.  Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

Authors:  Michelle B Mahler; Ying Taur; Raymond Jean; Nancy A Kernan; Susan E Prockop; Trudy N Small
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-04       Impact factor: 5.742

10.  Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.

Authors:  Puiying A Mak; George F Santos; Kelly-Anne Masterman; Jeff Janes; Bill Wacknov; Kay Vienken; Marzia Giuliani; Ann E Herman; Michael Cooke; M Lamine Mbow; John Donnelly
Journal:  Clin Vaccine Immunol       Date:  2011-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.